Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | TYK2 | P29597 | 1/20 | 0.50 |
| ▸ | BRAF | P15056 | 11/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
| ▸ | IDE | P14735 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25821615 | 0.95 | ACVRL1 (0.54) | ACVRL1POLBMAPTBRAF | |
| SCHEMBL24010909 | 0.88 | BRAF (0.53) | MAPTJAK2TYK2BRAFKDM4C | |
| SCHEMBL24010281 | 0.88 | MAPK8 (0.52) | ACVRL1POLBMAPTJAK2TYK2 | |
| SCHEMBL30290887 | 0.88 | MAPK8 (0.52) | ACVRL1POLBMAPTJAK2TYK2 | |
| SCHEMBL24003984 | 0.87 | KCNK3 (0.61) | POLBMAPTJAK2TYK2BRAF | |
| SCHEMBL24006041 | 0.87 | POLB (0.69) | POLBMAPTJAK2TYK2PTGS1 | |
| SCHEMBL24004060 | 0.85 | POLB (0.72) | ACVRL1POLBMAPTJAK2TYK2 | |
| SCHEMBL24010595 | 0.85 | KMT2A (0.51) | POLBMAPTJAK2TYK2PTGS1 | |
| SCHEMBL24010211 | 0.84 | MAPT (0.58) | POLBMAPTJAK2TYK2BRAF | |
| SCHEMBL7096462 | 0.83 | NT5E (0.68) | POLBMAPTJAK2TYK2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| WO-2021226458-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | ACVRL1 2666/4885POLB 2233/4885MAPT 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.